Streetbeat News

Stock Prices

KRMD

KORU Medical Systems (NASDAQ:KRMD) reported Q4 earnings, beating estimates with an EPS of $-0.02 against an expected $-0.04 but saw a revenue decrease of $159k from the previous year. Despite beating EPS estimates, past performance shows a share price drop following earnings beats.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 8:10 pm

GWH

ESS Tech (NYSE:GWH) reported Q4 earnings, beating estimates with an EPS of $-0.09 against an expected $-0.11 and saw a revenue increase of $2.78 million year-over-year. Despite beating last quarter's EPS estimates, the share price dropped by 9.0% the following day.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 8:10 pm

GWH

ESS Tech (NYSE:GWH) reported Q4 2023 earnings with a GAAP EPS of $(0.09), surpassing the $(0.11) estimate. However, their sales of $2.796M fell short of the $3.540M estimate, marking a significant increase from $16.000 thousand in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:09 pm

SCPH

scPharmaceuticals (NASDAQ:SCPH) reported Q4 2023 earnings with a GAAP EPS of $(0.35), surpassing the $(0.42) estimate, and sales of $6.096M, exceeding the $5.525M estimate. This represents a 16.67% decrease in losses per share compared to the same period last year, and a 10.33% increase in sales.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:07 pm

HOOD

Robinhood Markets reported a 16% increase in assets under custody at the end of February, reaching $118.7B. Additionally, equity notional trading volumes surged by 36%.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:06 pm

HLTH

Cue Health (NASDAQ:HLTH) reported Q4 2023 adjusted EPS of $(0.32), surpassing the $(0.44) estimate, with sales of $18.798M exceeding the $17.681M forecast. However, this represents an 87.19% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:05 pm

FTCI

FTC Solar (NASDAQ:FTCI) reported Q4 earnings with an EPS of $-0.08, missing estimates by -14%, and a revenue decrease of $3.02 million from the previous year. Despite past earnings misses, the company's share price increased by 6.0% the day after last quarter's earnings were announced.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 8:05 pm

CHRS

Coherus BioSciences (NASDAQ:CHRS) reported Q4 earnings with an EPS of $-0.62, missing estimates by -417.0% against an expected $-0.12. Revenue increased by $46.17 million from the same period last year. Despite beating EPS estimates in Q3 2023, the share price dropped by 30.0% the following day. The company's past earnings performance shows a pattern of fluctuating EPS and revenue figures.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 8:05 pm

CHRS

Coherus BioSciences (NASDAQ:CHRS) reported Q4 2023 adjusted EPS of $(0.62), missing the $(0.12) estimate, with sales of $91.524M also missing the $96.400M estimate. This represents a 101.81% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:03 pm

SPRB

Trading of Spruce Biosciences (SPRB) shares has been halted pending the release of code news. Investors are awaiting further details to understand the impact on the company's stock.

Portfolio Pulse from Happy Mohamed

March 13, 2024 | 8:02 pm